Analyst Speak:

“The Global Dengue Vaccine Market was valued around US$ 73 Mn by 2018 and growing at a significant CAGR of 44% over next seven years 2019-2025 due to rising prevalence of dengue”

The global dengue vaccine market accounted for US$ 73 Mn in 2018 and burgeoning over the forthcoming years. Some of the key factors propelling the market growth include increasing novel drug treatments, high acceptance and recognition in emerging markets, rising prevalence of dengue, improvements and advances in vaccines. However, lack of awareness amongst the rural population regarding this vaccines and high possibilities of side effect of vaccine are some major factors hindering the market growth. However, increasing approvals of vaccines by regulatory authorities provides huge growth opportunity for the market.

Global dengue vaccine market segmented on the basis of product type, vaccine type end user and region.

Avail Sample Report of the Market @ https://www.precisionbusinessinsights.com/request-sample?product_id=15690

Live Attenuated Vaccine dominate the Global Dengue Vaccine Market

Based on vaccine type, global dengue vaccine market is segmented live attenuated vaccine, killed vaccine and others. Live Attenuated Vaccine held considerable market growth during estimated period. Dengue is an expanding global health problem causing millions of infections each year. There is no exact medication for dengue other than case management. Therefore, the potential use of an efficient live attenuated vaccine against dengue would denote a remarkable addition to the prevention of this disease.

Live attenuated vaccines are created by weakening infectious organisms that can still replicate and induce protective immune responses without causing disease in the host. LAVs stimulate an excellent immune response that is nearly as good as compared to an infection with the wild-type pathogen. Vaccination with the live but attenuated organism generates an immune response that protects the vaccinated person against severe disease or even infection. Live attenuated vaccines represent one of the first successful methods of vaccination.

Asia Pacific Leads the Global Dengue Vaccine market

PBI’s global dengue vaccine market report analyses the market in different regions such as North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. According to regional analysis. Asia Pacific accounted for larger revenue share in global dengue vaccine market with considerable CAGR owing to rising health care industries and increase in government investment to develop health care infrastructure. Further, increasing incidence of dengue is the other major factor responsible for the market growth in this region. Also, the market in emerging countries like India and China is likely to grow owing to increasing awareness regarding dengue and its treatment.
 
Strategic Collaborations are the Key Strategies Adopted by Market Players

Global dengue vaccine market further reveals that the key players increasingly adopting strategies such as launch of newer products, frequent product approvals, and long term alliance to improve market revenue share and gaining significant geographic presence across the region. For Instance, in December 2018, Merck & Co., Inc. collaborated with Instituto Butantan to develop vaccines to protect against dengue infections.

Key player’s profiles in the report are Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), Insitituto Butantan (Brazil), Vabiotech (Vietnam), Panacea Biotech (India), Biological E (India), GlaxoSmithKline plc (U.K) and Merck & Co. Inc. (U.S.).

For More Information @ https://www.precisionbusinessinsights.com/market-reports/global-dengue-vaccine-market/

Precision Business Insights (PBI) in its report titled “Global Dengue Vaccine Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2014-2018 and Forecast 2019-2025” assesses the market performance over seven years forecast period over 2019-2025. The report analyses the market value forecast and provides the strategic insights into the market driving factors, challenges that are hindering the market revenue growth over forecast period. Moreover, the report also includes the total revenue and volume for the market.

Detailed Segmentation

By Product Type
o CYD-TDV (Dengvaxia)
o DENVax
o TetraVax-DV
o Others

By Vaccine Type
o Live Attenuated Vaccine
o Killed Vaccine
o Others

By End User
o Hospitals
o Clinics
o Government Institutes
o Non-Governmental Organization (NGOs)

By Geography
o North America
• US
• Canada
o Europe
• Germany
• France
• UK
• Italy
• Spain
• Russia
• Poland
• Rest of Europe
o Asia-Pacific
• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific
o Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
o Middle East and Africa (MEA)
• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa
• Rest of MEA

About Us:

Precision Business Insights is one of the leading market research and management consulting firm, run by a group of seasoned and highly dynamic market research professionals with a strong zeal to offer high-quality insights.

Contact Us:

Shreya Paul
Senior Business Development Executive
Email @ [email protected]
Call @ +1-866-598-1553
Precision Business Insights